Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Novo Nordisk announced a substantial price cut for its obesity drug Wegovy in India, with reductions of up to 37%. The starting weekly dose has dropped from Rs 4,336 to Rs 2,712, making the treatment more accessible. This revision covers all five available dose strengths. The company also noted that GST on the drug was previously reduced from 12% to 5% in September 2025, contributing to earlier price moderation.

This strategic pricing adjustment is part of Novo Nordisk's efforts to expand access to chronic weight management therapies and directly challenge rival drug Mounjaro by Eli Lilly, which recently became the top-selling brand in India by value. Novo Nordisk is also partnering with Emcure Pharmaceuticals to commercialize a second brand of Wegovy, aiming to utilize Emcure's extensive distribution network to reach beyond major metropolitan areas.

Vikrant Shrotriya, managing director of Novo Nordisk India, stated the revision aligns with their mission to offer effective, safe, and sustainable obesity treatment to Indians.

Impact: This price reduction is expected to significantly boost Wegovy's market penetration in India, potentially increasing Novo Nordisk's market share in the growing weight-loss drug segment. It intensifies competition, benefiting consumers with more affordable options. The partnership with Emcure Pharmaceuticals could also enhance Emcure's revenue streams and market presence. Rating: 6/10

Difficult Terms: * **Wegovy**: A brand name for a prescription medication used for chronic weight management. * **Mounjaro**: A competing weight-loss drug manufactured by Eli Lilly. * **GST (Goods and Services Tax)**: A unified indirect tax system implemented in India. * **Commercialize**: To introduce a new product into the market. * **Distribution network**: The system of organizations and individuals involved in moving a product from its producer to its consumer. * **Cardiovascular risk reduction**: Decreasing the likelihood of developing heart disease or stroke. * **Lifestyle modifications**: Changes to daily habits, such as diet and exercise, recommended for health improvement.